UNITED KINGDOM · UPCOMING

Helios Diagnostics (HEALUK)

Diagnostics issuer with defensive revenue mix, stable margins, and clean cash conversion. UK issue-quality lens.

Healthcare Diagnostics 75/100 High quality / expensive Confidence: Low Live United Kingdom

Shareable IPO scorecard

Composite 4.7/10 Score view

Valuation vs peers

5.6

Promoter quality

4.0

GMP signal

7.5

Listing-day risk

1.6

Share card

Turn the IPO scorecard into a simple image card for WhatsApp or social sharing without exposing the whole page.

The exported image uses the current issue name, verdict, and 0-10 scorecard.

Confidence and caution

Built as a stable research workflow for UK IPO review. Outputs focus on risk framing and valuation context rather than application language.
Risk posture: Limited-confidence review
Issue details reflect the latest structured filing data available in this workspace.
Issue size captured at about ₹640 crore.
Issue mix: fresh issue 84.0% and OFS 16.0% when available.

How to use these notes

Best used for

Comparing issue quality before opening the full filing.
Separating strengths, risk flags, and valuation context into one view.
Building a slower due-diligence checklist instead of reacting to IPO hype.

Use extra caution when

Peer valuation coverage is incomplete or extraction warnings are present.
The issue is OFS-heavy or use-of-proceeds is vague.
Governance, litigation, or contingent-liability flags are prominent.

Issue summary

Open date: 2026-05-19
Close date: 2026-05-21
Listing date: 2026-05-28
Issue size: ₹640 cr
Price band: 145-152
Lot size: 40
Fresh issue: 84.0%
OFS: 16.0%
Use of proceeds: Capex, Expansion

Scorecard

Overall: 75/100 High quality / expensive

Financial Quality 82

Business Quality 65

Issue Structure 82

Valuation Sanity 56

Governance Risk 84

Strengths

Operating cash flow is keeping up with profit.
Leverage looks manageable relative to equity.
Profit has stayed positive across the available years.
Cash conversion looks supportive rather than weak.
Sector profile is relatively stable compared with more cyclical issue types.
Cash flow history provides some support to the business narrative.

Risks

Customer or business concentration should be reviewed carefully.
Business concentration could make earnings more fragile than the headline story suggests.
Smaller-cap liquidity

Peer snapshot

Peer	Lens	Focus	P/E	EV/EBITDA	P/S
Synlab	Diagnostics peers	cash generation	24.0	12.0	2.9
Medica	healthcare services	defensive demand profile	18.0	10.0	2.0

Valuation context

Post-issue P/E: 21.0
Peer median P/E: 23.0
Post-issue EV/EBITDA: 11.0
Peer median EV/EBITDA: 12.0
Post-issue P/S: 2.7
Peer median P/S: 2.2

Risk flags

Limited scale versus larger peers
Smaller-cap liquidity

Why this could still be wrong

A linked filing document is not attached here, so confidence is capped below a fully evidenced issue review.

Due diligence checklist

Read the use-of-proceeds section line by line.
Check promoter pledges or any recent promoter share changes.
Verify related party transactions and whether they are recurring.
Understand customer and supplier concentration before relying on growth assumptions.
Compare issue valuation against listed peers, not just the issue narrative.
Review litigation, tax disputes, and contingent liabilities directly in the issue documents.
Understand customer, supplier, or geography concentration before taking the issue seriously.

Disclosure note

Research notes only. This output is for screening and education, not investment advice.
Issue documents, peer context, and risk disclosures should be read directly before any action.
IPO analysis can change as offer documents, dates, and issue structure details are updated.

Source hints

Pages: None yet
Page count: 0
Fields with evidence: 0
Linked filing attached: No
OCR used: No
Warnings: 0
Verdict context: High quality / expensive